Sign in
CompletedPhase 3

Noradrenaline plus placebo vs noradrenaline plus terlipressin for the treatment of septic shock

Key facts

Who runs it
Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla
Where
Spain10 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
152 people enrolled
Started
26 Jun 2024
Ended
28 Dec 2024
Type of study
Interventional
Record updated
29 August 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Adult patients (18 years or older)
  • Patients with septic shock
  • Patients with a SOFA index> 4 points. (If the patient is going to be intubated at the time of randomization, take the neurological SOFA score from the medical record)
  • Signature of the informed consent by the patient or his or her legal representative. (Informed consent may be granted by phone if the legal representative is not present at the center at the time of signing, with written re-consent required as soon as possible)

Who cannot take part

  • Previous use of terlipressin during your stay in the ICU
  • Previous use of vasopressin
  • Known allergy to terlipressin
  • Pathologies on which terlipressin is clinically indicated: gastrointestinal bleeding due to esophageal-gastric varices, hepatorenal syndrome
  • Patients diagnosed with unstable acute coronary syndrome
  • Patients with Raynaud's Phenomenon, or vasospastic disease
  • Patients with active bleeding
  • Pregnant or lactating patients
  • Patients with acute or chronic mesenteric ischemia
  • Patients participating in another intervention clinical trial
  • Patients with renal replacement technique at the time of randomization
  • Patients with some limitation of life support treatment (LLST)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Main objective is composed by: -Reduction of organ failure evaluated by Sepsis realted Organ failure Assessment score (SOFA scale) 72 h after administration of terlipressin / placebo. -Increase in ICU-free days of life measured 28 days after administration of terlipressin / placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock.
Record updated
29 August 2024